BIOMETRY

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.